nitrates has been researched along with Hypertension, Portal in 42 studies
Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.
Hypertension, Portal: Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We studied whether acute administration of NCX-1000, a nitric oxide (NO)-releasing derivative of ursodeoxycholic acid (UDCA), to animals with established liver cirrhosis decreases intrahepatic resistance and modulates hepatic vascular hypereactivity to norepinephrine (NE)." | 3.72 | NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver. ( Acuto, G; Antonelli, E; Baldoni, M; Brancaleone, V; Clerici, C; Del Soldato, P; Distrutti, E; Fiorucci, S; Morelli, A; Orlandi, S; Sanpaolo, L, 2003) |
| "Recent advances in the pharmacologic treatment of portal hypertension have mainly focused on modifying an increased intrahepatic resistance through nitric oxide and/or modulation of vasoactive substances." | 2.61 | Pharmacologic Management of Portal Hypertension. ( Bunchorntavakul, C; Reddy, KR, 2019) |
| "Carvedilol is a potent noncardioselective beta-blocker, with weak vasodilating properties because of alpha 1 blockade." | 2.46 | The role of carvedilol in the management of portal hypertension. ( Hayes, PC; Tripathi, D, 2010) |
| "Portal hypertension is a progressively debilitating complication of cirrhosis and a principal cause of mortality in patients who have hepatic decompensation." | 2.43 | Pharmacologic therapy of portal hypertension. ( Grace, ND; Minor, MA, 2006) |
| "For this reason, the ideal drug for the treatment of portal hypertension should act by decreasing intrahepatic vascular resistance, without worsening the splanchnic/systemic vasodilatation." | 2.42 | Treatment of portal hypertension with NCX-1000, a liver-specific NO donor. A review of its current status. ( Antonelli, E; Fiorucci, S; Morelli, A; Tocchetti, P, 2004) |
| "In conclusion, chronic administration of organic nitrates, allowing for a nitrate-free interval each day, to cirrhotic patients reduces portal pressure with a variable, dose-dependent effect on azygos blood flow." | 2.39 | Organic nitrates in portal hypertension. ( Hayes, PC; Jones, AL, 1994) |
| "The pharmacologic treatment of portal hypertension should be able to stop as well as to prevent variceal hemorrhage." | 2.38 | Pharmacologic treatment of portal hypertension. ( Groszmann, RJ; Rodríguez-Pérez, F, 1992) |
| "Portal hypertension is a common complication of liver cirrhosis and significantly increases mortality and morbidity." | 1.42 | Thalidomide ameliorates portal hypertension via nitric oxide synthase independent reduced systolic blood pressure. ( Korshunov, VA; Maluccio, MA; Skill, NJ; Theodorakis, NG; Wang, YN, 2015) |
| "CBDL rats show hypoxemia with intrapulmonary vasodilatation (IPVD), and are recognized as a model of hepatopulmonary syndrome (HPS), while PVL rats are normoxemic." | 1.33 | Arterial hypoxemia and intrapulmonary vasodilatation in rat models of portal hypertension. ( Akimoto, T; Kato, Y; Katsuta, Y; Komeichi, H; Miyamoto, A; Ohsuga, M; Satomura, K; Shimizu, S; Takano, T; Zhang, XJ, 2005) |
| "Portal hypertension was present at 12 weeks (11 +/- 0." | 1.33 | A stable model of cirrhotic portal hypertension in the rat: thioacetamide revisited. ( Fevery, J; Laleman, W; Libbrecht, L; Nevens, F; Roskams, T; Servaes, R; Vander Elst, I; Zeegers, M, 2006) |
| " These changes were prevented by chronic administration of NAC." | 1.30 | N-acetylcysteine prevents development of the hyperdynamic circulation in the portal hypertensive rat. ( Anand, R; Fernando, B; Hamilton, G; Harry, D; Holt, S; Marley, R; Moore, K; Sanderson, P; Smith, R, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.38) | 18.7374 |
| 1990's | 12 (28.57) | 18.2507 |
| 2000's | 22 (52.38) | 29.6817 |
| 2010's | 7 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bunchorntavakul, C | 1 |
| Reddy, KR | 1 |
| Theodorakis, NG | 1 |
| Wang, YN | 1 |
| Korshunov, VA | 1 |
| Maluccio, MA | 1 |
| Skill, NJ | 1 |
| Berzigotti, A | 1 |
| Bellot, P | 1 |
| De Gottardi, A | 1 |
| Garcia-Pagan, JC | 1 |
| Gagnon, C | 1 |
| Spénard, J | 1 |
| Bosch, J | 2 |
| Tripathi, D | 1 |
| Hayes, PC | 2 |
| Huang, HC | 1 |
| Wang, SS | 1 |
| Lee, JY | 1 |
| Chen, YC | 1 |
| Lee, FY | 4 |
| Lin, HC | 4 |
| Chang, CC | 1 |
| Lee, SD | 4 |
| Kajita, M | 1 |
| Murata, T | 1 |
| Horiguchi, K | 1 |
| Iizuka, M | 1 |
| Hori, M | 1 |
| Ozaki, H | 1 |
| Afzelius, P | 1 |
| Bazeghi, N | 1 |
| Bie, P | 1 |
| Bendtsen, F | 1 |
| Vestbo, J | 1 |
| Møller, S | 1 |
| Arkenau, HT | 1 |
| Stichtenoth, DO | 1 |
| Frölich, JC | 1 |
| Manns, MP | 1 |
| Böker, KH | 1 |
| Merkel, C | 1 |
| Fiorucci, S | 4 |
| Antonelli, E | 4 |
| Morelli, A | 4 |
| Mookerjee, RP | 1 |
| Sen, S | 1 |
| Davies, NA | 1 |
| Hodges, SJ | 1 |
| Williams, R | 1 |
| Jalan, R | 1 |
| Yang, YY | 3 |
| Lee, WC | 2 |
| Huang, YT | 3 |
| Hou, MC | 3 |
| Chang, FY | 3 |
| Tahan, V | 1 |
| Avsar, E | 1 |
| Karaca, C | 1 |
| Uslu, E | 1 |
| Eren, F | 1 |
| Aydin, S | 1 |
| Uzun, H | 1 |
| Hamzaoglu, HO | 1 |
| Besisik, F | 1 |
| Kalayci, C | 1 |
| Okten, A | 1 |
| Tozun, N | 1 |
| Brancaleone, V | 1 |
| Sanpaolo, L | 1 |
| Orlandi, S | 1 |
| Distrutti, E | 1 |
| Acuto, G | 1 |
| Clerici, C | 1 |
| Baldoni, M | 1 |
| Del Soldato, P | 2 |
| Loureiro-Silva, MR | 1 |
| Cadelina, GW | 1 |
| Iwakiri, Y | 1 |
| Groszmann, RJ | 3 |
| Tocchetti, P | 1 |
| Abraldes, JG | 1 |
| Katsuta, Y | 1 |
| Zhang, XJ | 1 |
| Ohsuga, M | 1 |
| Akimoto, T | 1 |
| Komeichi, H | 1 |
| Shimizu, S | 1 |
| Kato, Y | 1 |
| Miyamoto, A | 1 |
| Satomura, K | 1 |
| Takano, T | 1 |
| Rockey, DC | 1 |
| Laleman, W | 1 |
| Vander Elst, I | 1 |
| Zeegers, M | 1 |
| Servaes, R | 1 |
| Libbrecht, L | 1 |
| Roskams, T | 1 |
| Fevery, J | 1 |
| Nevens, F | 1 |
| Minor, MA | 1 |
| Grace, ND | 2 |
| Ladero Quesada, JM | 1 |
| Henriksen, JH | 1 |
| Ring-Larsen, H | 1 |
| Jones, AL | 1 |
| El-Newihi, HM | 1 |
| Kanji, VK | 1 |
| Mihas, AA | 1 |
| Lebrec, D | 3 |
| Fernando, B | 1 |
| Marley, R | 1 |
| Holt, S | 1 |
| Anand, R | 1 |
| Harry, D | 1 |
| Sanderson, P | 1 |
| Smith, R | 1 |
| Hamilton, G | 1 |
| Moore, K | 1 |
| Hori, N | 1 |
| Wiest, R | 1 |
| Gadano, AC | 1 |
| Sogni, P | 1 |
| Heller, J | 1 |
| Moreau, R | 1 |
| Bories, PN | 1 |
| Piscaglia, F | 1 |
| Gaiani, S | 1 |
| Donati, G | 1 |
| Masi, L | 1 |
| Bolondi, L | 1 |
| Sanyal, AJ | 1 |
| Angelico, M | 1 |
| Lionetti, R | 1 |
| Lee, TY | 2 |
| Morelli, O | 1 |
| Mencarelli, A | 1 |
| Casini, A | 1 |
| Mello, T | 1 |
| Palazzetti, B | 1 |
| Tallet, D | 1 |
| Lowe, RC | 1 |
| Luketic, VA | 1 |
| Zhu, J | 1 |
| Wang, D | 1 |
| Leng, X | 1 |
| Zhang, Z | 1 |
| Wang, F | 1 |
| Peng, J | 1 |
| Du, R | 1 |
| Liu, RS | 1 |
| Rodríguez-Pérez, F | 1 |
| Vorob'ev, LP | 1 |
| Maev, IV | 1 |
| Reichen, J | 2 |
18 reviews available for nitrates and Hypertension, Portal
| Article | Year |
|---|---|
Pharmacologic Management of Portal Hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Anticoagulants; Antihypertensi | 2019 |
The role of carvedilol in the management of portal hypertension.
Topics: Antihypertensive Agents; Ascites; Benzopyrans; Carbazoles; Carvedilol; Drug Therapy, Combination; Et | 2010 |
Nonselective beta-blockers plus nitrates in portal hypertension: an open question.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Humans; Hypertension, Portal; Nitrates | 2003 |
Treatment of portal hypertension with NCX-1000, a liver-specific NO donor. A review of its current status.
Topics: Animals; Clinical Trials as Topic; Humans; Hypertension, Portal; Liver; Nitrates; Nitric Oxide; Nitr | 2004 |
Variceal bleeding: pharmacological therapy.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Hemorrhage; Humans; Hypertension, Portal; Liver; | 2005 |
Pharmacologic therapy for gastrointestinal bleeding due to portal hypertension and esophageal varices.
Topics: Adrenergic beta-Antagonists; Algorithms; Antihypertensive Agents; Cardiovascular Agents; Esophageal | 2006 |
Pharmacologic therapy of portal hypertension.
Topics: Adrenergic beta-Antagonists; Humans; Hypertension, Portal; Nitrates; Somatostatin; Vasoconstrictor A | 2006 |
Renal effects of drugs used in the treatment of portal hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Calcium Channel Blockers | 1993 |
Organic nitrates in portal hypertension.
Topics: Animals; Collateral Circulation; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans | 1994 |
Review: pharmacotherapeutic agents in the treatment of portal hypertension.
Topics: Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Forecasting; Gastrointestinal Hemorrhag | 1997 |
Doppler evaluation of the effects of pharmacological treatment of portal hypertension.
Topics: Adrenergic Agents; Adrenergic beta-Antagonists; Antihypertensive Agents; Calcium Channel Blockers; D | 1999 |
Long-acting nitrates in portal hypertension: to be or not to be?
Topics: Adrenergic beta-Antagonists; Delayed-Action Preparations; Esophageal and Gastric Varices; Female; Ga | 2001 |
Primary prophylaxis of variceal hemorrhage.
Topics: Adrenergic beta-Antagonists; Endoscopy; Esophageal and Gastric Varices; Hemorrhage; Humans; Hyperten | 2001 |
Management of portal hypertension after variceal hemorrhage.
Topics: Adrenergic beta-Antagonists; Catheterization; Endoscopy; Hemodynamics; Hemorrhage; Humans; Hypertens | 2001 |
Pharmacologic treatment of portal hypertension.
Topics: Adrenergic beta-Antagonists; Animals; Calcium Channel Blockers; Clonidine; Gastrointestinal Hemorrha | 1992 |
[New trends in the treatment of hemodynamic disorders in liver cirrhosis].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Calcium Channel Blockers; Drug Evaluation; Hem | 1991 |
Liver function and pharmacological considerations in pathogenesis and treatment of portal hypertension.
Topics: Blood Circulation; Calcium Channel Blockers; Fibrosis; Humans; Hypertension, Portal; Liver; Methods; | 1990 |
The effect of drugs on the portal circulation.
Topics: Blood Flow Velocity; Blood Pressure; Calcium Channel Blockers; Hemodynamics; Humans; Hypertension, P | 1987 |
1 trial available for nitrates and Hypertension, Portal
| Article | Year |
|---|---|
NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study.
Topics: Administration, Oral; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administrati | 2010 |
23 other studies available for nitrates and Hypertension, Portal
| Article | Year |
|---|---|
Thalidomide ameliorates portal hypertension via nitric oxide synthase independent reduced systolic blood pressure.
Topics: Animals; Antihypertensive Agents; Aorta, Abdominal; Arterial Pressure; Biomarkers; Blood Flow Veloci | 2015 |
Simvastatin effects on portal-systemic collaterals of portal hypertensive rats.
Topics: Animals; Arginine Vasopressin; Collateral Circulation; Cyclooxygenase 1; Cyclooxygenase 2; Dinoprost | 2010 |
iNOS expression in vascular resident macrophages contributes to circulatory dysfunction of splanchnic vascular smooth muscle contractions in portal hypertensive rats.
Topics: Animals; Calcium; Cyclic GMP; Hypertension, Portal; Lipopolysaccharides; Liver Cirrhosis; Macrophage | 2011 |
Circulating nitric oxide products do not solely reflect nitric oxide release in cirrhosis and portal hypertension.
Topics: Adult; Aged; Biomarkers; Breath Tests; Case-Control Studies; Denmark; Female; Heart Rate; Hemodynami | 2011 |
Elevated nitric oxide levels in patients with chronic liver disease and cirrhosis correlate with disease stage and parameters of hyperdynamic circulation.
Topics: Ascites; Data Interpretation, Statistical; Esophageal and Gastric Varices; Hemodynamics; Hepatitis, | 2002 |
Nitric oxide and portal hypertension: a nitric oxide-releasing derivative of ursodeoxycholic acid that selectively releases nitric oxide in the liver.
Topics: Adipocytes; Animals; Humans; Hypertension, Portal; Liver; Liver Cirrhosis; Nitrates; Nitric Oxide; U | 2003 |
Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis.
Topics: Adult; Aged; Antibodies, Monoclonal; Blood Pressure; Female; Gastrointestinal Agents; Heart Rate; He | 2003 |
Plasma erythropoietin level in patients with cirrhosis and its relationship to the severity of cirrhosis and renal function.
Topics: Anemia; Ascites; Blood Pressure; Cardiac Output; Erythropoietin; Hepatic Veins; Humans; Hypertension | 2003 |
Adrenomedullin in cirrhotic and non-cirrhotic portal hypertension.
Topics: Adrenomedullin; Adult; Female; Humans; Hypertension, Portal; Liver Cirrhosis; Male; Middle Aged; Nit | 2003 |
NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver.
Topics: Animals; Bile; Blood Pressure; Drug Interactions; Hypertension, Portal; In Vitro Techniques; Liver C | 2003 |
A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats.
Topics: Animals; Drug Interactions; Hypertension, Portal; Liver Circulation; Liver Cirrhosis; Male; Mesenter | 2003 |
Arterial hypoxemia and intrapulmonary vasodilatation in rat models of portal hypertension.
Topics: Animals; Arteries; Disease Models, Animal; Endothelin-1; Hepatopulmonary Syndrome; Hypertension, Por | 2005 |
A stable model of cirrhotic portal hypertension in the rat: thioacetamide revisited.
Topics: Administration, Oral; Analysis of Variance; Animals; Carcinogens; Hemodynamics; Hypertension, Portal | 2006 |
[Vasodilators in portal hypertension].
Topics: Calcium Channel Blockers; Clonidine; Humans; Hypertension, Portal; Nitrates; Serotonin Antagonists; | 1994 |
Activity of gastric mucosal nitric oxide synthase in portal hypertensive gastropathy.
Topics: Adult; Aged; Esophageal and Gastric Varices; Gastric Mucosa; Humans; Hypertension, Portal; Liver Cir | 1996 |
N-acetylcysteine prevents development of the hyperdynamic circulation in the portal hypertensive rat.
Topics: Acetylcysteine; Animals; Dinoprost; Hemodynamics; Hypertension, Portal; Male; Nitrates; Nitric Oxide | 1998 |
Enhanced release of nitric oxide in response to changes in flow and shear stress in the superior mesenteric arteries of portal hypertensive rats.
Topics: Animals; Hypertension, Portal; Male; Mesenteric Arteries; Nitrates; Nitric Oxide; Nitrites; Perfusio | 1998 |
Vascular nitric oxide production during the development of two experimental models of portal hypertension.
Topics: Animals; Aorta, Thoracic; Disease Models, Animal; Guanidines; Hypertension, Portal; In Vitro Techniq | 1999 |
Hepatic venous pressure gradient: to measure or not to measure, that is the question.
Topics: Adrenergic beta-Antagonists; Drug Synergism; Esophageal and Gastric Varices; Hemorrhage; Hepatic Vei | 2000 |
Adaptive vasodilatory response after octreotide treatment.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aorta; Blotting, Western; Cyclooxygenase Inhibitors; Dose-Res | 2001 |
NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension.
Topics: Animals; Carbon Tetrachloride; Collagen; Hypertension, Portal; Liver; Liver Cirrhosis; Male; Nitrate | 2001 |
[The role of nitric oxide in the pathogenesis of portal hypertension].
Topics: Endotoxins; Female; Humans; Hypertension, Portal; Liver Diseases; Liver Function Tests; Male; Middle | 2000 |
Effect of 1-week losartan administration on bile duct-ligated cirrhotic rats with portal hypertension.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blotting, Western; Common Bile Duct; Enzyme Inhibi | 2002 |